Earn credits and unlock exclusive offers with iXCells Loyalty Program!

Human iPS Cell Line (Alzheimer’s Disease Patient, PSEN2, N141I, HET)

SKU: 30HU-008

Human iPS Cell Line (Alzheimer’s Disease Patient, PSEN2, N141I, HET)

SKU: 30HU-008
Pricing Starting at

Starting at: $1,897.00

Available Options

SKUPackage SizePriceQuantityAdd to Cart
30HU-008Cryopreserved, 0.5-1.0 million cells/vialStarting at: $1,897.00

Associated Products


Product Description

Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD patients suffer from slow deterioration of memory and cognitive functions, which may eventually lead to death. AD is the most common form of dementia and it is estimated that more than 6 million American are living with AD in 2019. The genetic causes are largely unknown in sporadic AD (sAD) while few genetic aberrations have been identified in familiar AD (fAD). However, no effective treatments have been developed to slow down or change the disease course.

iXCells Biotechnologies have generated human induced pluripotent stem cells (hiPSCs) derived from a patient with familiar Alzheimer’s disease (fAD). These iPS cells are established from a single clone and expanded in feeder-free conditions. The Certificate of Analysis (COA) is provided for each cell lot purchased. The cells have been fully characterized for their self-renewal and pluripotent markers (Figure 1). All the cells provided by iXCells Biotechnologies are negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C. Recently, hiPSCs have been shown to serve as a versatile tool to investigate and model various diseases including AD and other neurodegenerative diseases. Therefore, our hiPSCs carrying fAD mutation (PSEN2 N141I) will meet the clients’ need to study the molecular basis of AD progression and further to develop potential therapeutic approaches.

Normal human iPS cell lines are available as separate products (Cat# 30HU-002). In addition, we provide human iPSC lines derived from individuals diagnosed with various diseases including Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Type 2 Diabetes (T2D). More disease-associated human iPS cell lines are under development. We also provide custom iPSC generation, gene editing and iPSC differentiation services to meet your needs.

Picture 1 30HU 008Figure 1. Characterization of human AD iPSC. Our human AD hiPSCs show typical human embryonic stem cell morphology (Phase Contrast) and strong alkaline phosphatase activity (AP).These cells also obtain strong self-renewal and pluripotent markers (OCT-3/4, NANOG, TRA-1-81, and TRA-1-60). Cell nuclei were stained with DAPI as counter staining. Scale bars are depicted in each panel.


Product Details

Tissue Origin Human iPS Cells derived from dermal fibroblasts of a Alzheimer’s Disease patient.The patient was diagnosed with TYPE 4 AD with a heterozygous N141I mutation in PSEN2 gene.
Package Size ~0.5-1.0 millioncells/vial
Shipped Cryopreserved
Storage Liquid nitrogen
Growth Properties Adherent
Media Human iPSC Growth Medium(Cat# MD-0018)

Human iPSC Feeder-Free Growth Medium(Cat# MD-0019)

Human iPSC Xeno-Free Growth Medium(Cat#0074)

iMEF Feeder (CF1), irradiated(Cat# 10MU-001)

Manuals & Protocols

  • Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nature Methods. 2011 May; 8(5):409-12. -- Learn More

  • Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., & Cenciarelli, C. (2021). Generation of gene edited hipsc from familial alzheimer's disease patient carrying N141I missense mutation in Presenilin 2. Stem Cell Research, 56, 102552. https://doi.org/10.1016/j.scr.2021.102552 -- Learn More